Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novocure Ltd Ord Sh
(NQ:
NVCR
)
19.44
-0.31 (-1.57%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Novocure Ltd Ord Sh
< Previous
1
2
3
4
5
6
7
Next >
ROSEN, SKILLED INVESTOR COUNSEL, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVCR
June 25, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Calling All Investors in NovoCure Limited (NVCR): New Lawsuit Lead Plaintiff Deadline is August 18, 2023 - Contact Bronstein, Gewirtz & Grossman, LLC Today
June 23, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of NovoCure Limited (NVCR) Investors
June 23, 2023
From
Kirby McInerney LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NovoCure Limited (NVCR) Investors
June 22, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NovoCure Limited (NVCR) Investors
June 22, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Calling All Investors in NovoCure Limited (NVCR): New Lawsuit Lead Plaintiff Deadline Is August 18, 2023 - Contact Bronstein, Gewirtz & Grossman, LLC Today
June 22, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NovoCure Limited (NVCR) Investors
June 21, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
EQUITY ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages NovoCure Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – NVCR
June 21, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against NovoCure Limited (NASDAQ: NVCR); Lead Plaintiff Deadline is August 18, 2023
June 21, 2023
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against NovoCure Limited (NVCR)
June 20, 2023
From
Robbins LLP
Via
Business Wire
NOVOCURE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NovoCure Limited - NVCR
June 20, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
NVCR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that NovoCure Limited Investors with Substantial Losses Have Opportunity to Lead the NovoCure Class Action Lawsuit
June 20, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
NOVOCURE LIMITED (NASDAQ: NVCR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against NovoCure Limited
June 20, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
June 20, 2023
From
The Schall Law Firm
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NovoCure Limited with Losses of $100,000 to Contact the Firm
June 19, 2023
From
The Schall Law Firm
Via
Business Wire
NOVOCURE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NovoCure Limited and Encourages Investors to Contact the Firm
June 19, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
June 16, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Announces Investigation into NovoCure Limited (NVCR)
June 16, 2023
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
June 15, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of NovoCure Limited (NVCR) on Behalf of Investors
June 15, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
June 07, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NovoCure Limited and Encourages Investors with Losses to Contact the Firm
June 06, 2023
From
The Schall Law Firm
Via
Business Wire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
June 06, 2023
From
Zai Lab Limited
Via
GlobeNewswire
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
June 06, 2023
From
Novocure
Via
Business Wire
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
June 01, 2023
From
Novocure
Via
Business Wire
Novocure Reports First Quarter 2023 Financial Results
May 04, 2023
From
Novocure
Via
Business Wire
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Novocure
Via
Business Wire
Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
April 14, 2023
From
Novocure
Via
Business Wire
Novocure to Report First Quarter 2023 Financial Results
April 03, 2023
From
Novocure
Via
Business Wire
Kristin Stafford Joins Novocure Board of Directors
March 29, 2023
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.